Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fed Conditions

Inclusion Criteria: * Males, non-smokers, between 18-55 years of age * Subjects' weight will be within 15% of their ideal weight based on the Table of "Desirable Weight of Adults", Metropolitan Life Insurance Company, 1983. * Subjects should read, sign, and date an Informed Consent Form prior to any study procedures * Subjects must complete all screening procedures within 28 days prior to the administration of the study medication. Exclusion Criteria: * Clinically significant abnormalities found during medical screening * Any clinically significant history of ongoing gastrointestinal problems or problems known to interfere with the absorption, distribution, metabolism or excretion of drugs (e.g. chronic diarrhea, inflammatory bowel diseases). * Clinically significant illnesses within 4 weeks of the administration of study medication. * Abnormal laboratory test judged clinically significant. * ECG or vital signs abnormalities (clinically significant). * History of allergic reactions to doxycycline or other related drugs (e.g., chlortetracycline, demeclocycline, minocycline and tetracycline). * History of allergic reactions to heparin. * Any food allergies, intolerances, restrictions, or special diet which in the opinion of the medical sub-investigator, contraindicates the subject's participation in this study. * Positive urine drug screen (see section VIII) at screening * Positive testing for hepatitis B, hepatitis C or HIV screening. * Use of an investigational drug or par…